IOBT IO Biotech Inc
Price (delayed)
$1.07
Market cap
$70.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.45
Enterprise value
$12.38M
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins,
Highlights
IO Biotech's debt has decreased by 23% YoY and by 5% QoQ
The company's EPS rose by 27% YoY but it fell by 12% QoQ
The quick ratio has dropped by 66% year-on-year and by 38% since the previous quarter
IO Biotech's equity has shrunk by 65% YoY and by 35% QoQ
Key stats
What are the main financial stats of IOBT
Market
Valuations
Earnings
Shares outstanding
65.88M
Market cap
$70.49M
Enterprise value
$12.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$95.18M
Net income
-$95.49M
EBIT
-$94.05M
EBITDA
-$93.2M
Free cash flow
-$82.39M
Per share
Balance sheet
Liquidity
EPS
-$1.45
EPS diluted
-$1.45
Free cash flow per share
-$1.25
Book value per share
$0.71
Revenue per share
$0
TBVPS
$1.03
Total assets
$67.7M
Total liabilities
$20.68M
Debt
$1.92M
Equity
$47.02M
Working capital
$45.47M
Debt to equity
0.04
Current ratio
3.33
Quick ratio
3.08
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-96.1%
Return on equity
-115.3%
Return on invested capital
N/A
Return on capital employed
-195.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IOBT stock price
How has the IO Biotech stock price performed over time
Intraday
7.41%
1 week
-10.83%
1 month
13.23%
1 year
-37.43%
YTD
16.3%
QTD
-1.83%
Financial performance
How have IO Biotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$95.18M
Net income
-$95.49M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 11% YoY and by 6% from the previous quarter
The company's operating income fell by 4.1% YoY
Growth
What is IO Biotech's growth rate over time
Valuation
What is IO Biotech stock price valuation
P/E
N/A
P/B
1.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 27% YoY but it fell by 12% QoQ
IO Biotech's equity has shrunk by 65% YoY and by 35% QoQ
The stock's price to book (P/B) is 40% more than its last 4 quarters average of 1.0
Efficiency
How efficient is IO Biotech business performance
The return on equity has dropped by 74% year-on-year and by 33% since the previous quarter
IOBT's return on assets has dropped by 61% year-on-year and by 28% since the previous quarter
Dividends
What is IOBT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IOBT.
Financial health
How did IO Biotech financials performed over time
The quick ratio has dropped by 66% year-on-year and by 38% since the previous quarter
The current ratio has dropped by 64% year-on-year and by 38% since the previous quarter
IO Biotech's debt is 96% lower than its equity
The debt to equity has surged by 100% year-on-year and by 33% since the previous quarter
IO Biotech's equity has shrunk by 65% YoY and by 35% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.